Chicago Partners Investment Group LLC Buys 854 Shares of Edwards Lifesciences Corporation $EW

Chicago Partners Investment Group LLC lifted its stake in Edwards Lifesciences Corporation (NYSE:EW) by 12.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,479 shares of the medical research company’s stock after buying an additional 854 shares during the period. Chicago Partners Investment Group LLC’s holdings in Edwards Lifesciences were worth $575,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in EW. Nuveen LLC bought a new stake in shares of Edwards Lifesciences in the first quarter valued at approximately $330,881,000. Jennison Associates LLC lifted its stake in Edwards Lifesciences by 34.3% during the first quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company’s stock worth $731,036,000 after purchasing an additional 2,576,383 shares during the last quarter. Mirova US LLC lifted its stake in Edwards Lifesciences by 56.2% during the second quarter. Mirova US LLC now owns 2,931,297 shares of the medical research company’s stock worth $229,257,000 after purchasing an additional 1,054,301 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Edwards Lifesciences during the second quarter worth $67,832,000. Finally, Woodline Partners LP lifted its stake in Edwards Lifesciences by 7,805.0% during the first quarter. Woodline Partners LP now owns 825,358 shares of the medical research company’s stock worth $59,822,000 after purchasing an additional 814,917 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Stock Performance

NYSE EW opened at $76.03 on Wednesday. The company has a market capitalization of $44.64 billion, a price-to-earnings ratio of 10.94, a PEG ratio of 3.61 and a beta of 1.05. Edwards Lifesciences Corporation has a twelve month low of $64.89 and a twelve month high of $83.00. The stock has a fifty day simple moving average of $77.46 and a 200 day simple moving average of $76.25. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.62 by $0.05. The business had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.Edwards Lifesciences’s quarterly revenue was up 11.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Sell-side analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the sale, the insider directly owned 206,900 shares in the company, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Daniel J. Lippis sold 4,114 shares of the stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the sale, the vice president owned 22,002 shares of the company’s stock, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.34% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. William Blair upgraded Edwards Lifesciences to a “strong-buy” rating in a research note on Friday, July 25th. Royal Bank Of Canada upped their price target on shares of Edwards Lifesciences from $85.00 to $89.00 and gave the stock an “outperform” rating in a report on Friday, July 25th. The Goldman Sachs Group reiterated a “buy” rating on shares of Edwards Lifesciences in a report on Friday, July 25th. Wells Fargo & Company upped their price target on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the stock an “overweight” rating in a report on Thursday, August 7th. Finally, Evercore ISI set a $88.00 price target on shares of Edwards Lifesciences and gave the stock an “outperform” rating in a report on Tuesday, October 7th. Three analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $87.06.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.